Please ensure Javascript is enabled for purposes of website accessibility

Why Hasn't Inovio Won a Huge Coronavirus Vaccine Deal from Washington Yet?

By Keith Speights - Aug 6, 2020 at 6:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are several reasons why the U.S. government might be choosing not to back the development of INO-4800 with big money, but two stand out.

So far, the U.S. government has awarded more than $6 billion to companies developing potential COVID-19 vaccines -- and not all of these funds have gone to American companies. U.K.-based drugmaker AstraZeneca (AZN -1.80%), for example, received up to $1.2 billion in funding from the Biomedical Advanced Research and Development Authority (BARDA) in May.

U.S.-based biotech Inovio Pharmaceuticals (INO -5.38%), though, has gotten the short end of the stick when it comes to federal financial support for its COVID-19 vaccine candidate, INO-4800. Sure, the Defense Department awarded it a $71 million contract to manufacture its Cellectra smart devices, which would be used to administer INO-4800. But that's chump change compared to the agreements worth close to $1 billion and a lot more that other drugmakers have secured.

Why hasn't Inovio won a huge coronavirus vaccine deal from Washington, D.C., yet? 

COVID-19 vaccines on top of $100 bills

Image source: Getty Images.

Possible reasons

There are several potential reasons behind Inovio's lack of a high-dollar agreement with the U.S. government. One that comes to mind is that INO-4800 isn't as far along in the clinical testing process as the COVID-19 vaccine candidates of rivals such as AstraZeneca and Moderna.

Both of those companies have already advanced their candidates into late-stage testing. INO-4800 is still in phase 1/2. Inovio hopes to kick off phase 2/3 clinical trials this summer. At this point, though, it remains uncertain when those studies will begin.

It could also be that U.S. decision-makers simply don't have a good feeling about INO-4800's prospects. While Inovio reported positive interim results from its phase 1 study, it didn't provide details about the production of neutralizing antibodies -- something that scientists highly prioritize in vaccines since those antibodies are what give them the potential to prevent viral infections.

Then too, Inovio is smaller than many of the drugmakers that have landed contracts. The U.S. government could be more comfortable dealing with established industry majors like AstraZeneca and Pfizer

Holes in the arguments

All of the above theories about why Inovio hasn't received hefty financial support from the U.S. government seem plausible. However, there are holes in each one.

Inovio's INO-4800 is certainly behind the candidates of AstraZeneca, Moderna, and a few others in terms of clinical progress. However, Sanofi (SNY -3.94%) and GlaxoSmithKline (GSK -6.71%) recently won a $2.1 billion deal with the U.S. -- and their experimental COVID-19 vaccine hasn't even started clinical testing yet.

That huge Sanofi-GSK agreement also seems to undercut the idea that U.S. officials aren't optimistic about the prospects for INO-4800. After all, it's hard to make the case that a vaccine candidate that hasn't been tested in people at all is more promising than one that has demonstrated overall immune responses in human trial subjects.

As for Inovio's relatively small size, that doesn't hold water either. Novavax (NVAX -2.47%) and Inovio have had similar market caps throughout most of 2020. But Novavax won a $1.6 billion deal with the U.S. government in early July.

Two other possibilities

There are two other possibilities that I suspect do directly relate to Inovio's lack of a major agreement with the U.S. government thus far. First, the problem could be that Inovio simply doesn't have the level of political connections that its rivals have. Second, its manufacturing capacity isn't as great as that of other drugmakers.

Don't discount the impact that the right political connections can have when it comes to landing government deals. Big pharma companies lobby actively in Washington, D.C., and contribute to political campaigns. Novavax isn't a large drugmaker, but a New York Times article last month highlighted the biotech's influential connections within the federal government. 

My hunch, though, is that the more critical issue hurting Inovio is its manufacturing capacity. Inovio stated in April that it plans to produce 1 million doses of INO-4800 by the end of 2020. That's a drop in the bucket compared to what other companies can produce, including Novavax.

How concerning should this be to investors? Inovio still has a shot at securing a major supply agreement. But to do so, INO-4800 will probably have to demonstrate overwhelmingly positive efficacy and safety in late-stage studies. If that happens, this biotech stock will skyrocket. And it's likely that the company's relative lack of political influence and its currently low manufacturing capacity will be quickly forgotten as federal money flows into its coffers.

Keith Speights owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$2.46 (-5.38%) $0.14
Sanofi Stock Quote
Sanofi
SNY
$43.42 (-3.94%) $-1.78
GSK Stock Quote
GSK
GSK
$35.73 (-6.71%) $-2.57
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$64.65 (-1.80%) $-1.19
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$40.34 (-2.47%) $-1.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.